CN102512358B - Rifaximin vaginal suppository for livestock and preparation method for same - Google Patents
Rifaximin vaginal suppository for livestock and preparation method for same Download PDFInfo
- Publication number
- CN102512358B CN102512358B CN 201110425645 CN201110425645A CN102512358B CN 102512358 B CN102512358 B CN 102512358B CN 201110425645 CN201110425645 CN 201110425645 CN 201110425645 A CN201110425645 A CN 201110425645A CN 102512358 B CN102512358 B CN 102512358B
- Authority
- CN
- China
- Prior art keywords
- rifaximin
- solid dispersion
- weight
- weight portion
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003040 rifaximin Drugs 0.000 title claims abstract description 93
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000006216 vaginal suppository Substances 0.000 title claims abstract description 23
- 229940120293 vaginal suppository Drugs 0.000 title claims abstract description 22
- 244000144972 livestock Species 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000007962 solid dispersion Substances 0.000 claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000829 suppository Substances 0.000 claims abstract description 20
- 235000011187 glycerol Nutrition 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 15
- 235000019322 gelatine Nutrition 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000002844 melting Methods 0.000 claims abstract description 13
- 230000008018 melting Effects 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 238000001816 cooling Methods 0.000 claims abstract description 8
- 239000001828 Gelatine Substances 0.000 claims abstract description 3
- 239000000758 substrate Substances 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 10
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 6
- 229960004756 ethanol Drugs 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 239000005844 Thymol Substances 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 5
- 229960000790 thymol Drugs 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- 239000008118 PEG 6000 Substances 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 4
- 239000010642 eucalyptus oil Substances 0.000 claims description 4
- 229940044949 eucalyptus oil Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 238000007500 overflow downdraw method Methods 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 3
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229960001859 domiphen bromide Drugs 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 17
- 239000011159 matrix material Substances 0.000 abstract description 9
- 239000006185 dispersion Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 238000010025 steaming Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 12
- 239000008273 gelatin Substances 0.000 description 12
- 235000011852 gelatine desserts Nutrition 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000002511 suppository base Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000004145 Endometritis Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000034801 Enterobacteriaceae Infections Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229940062280 rifamycin sodium Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229950003874 sulfamonomethoxine Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Abstract
The invention belongs to the field of veterinary medicine, and particularly relates to a rifaximin vaginal suppository for livestock and a preparation method for the same. The suppository contains the following components: 8.5-25.5 parts by weight of rifaximin solid dispersion, 30-88 parts by weight of matrix, 6.0-12.5 parts by weight of water, 0.01-1.0 parts by weight of surfactant, 0.01-10.0 parts by weight of synergist and 0.01-5.0 parts by weight of preservative, wherein the rifaximin solid dispersion is obtained by melting 7.3-21.9 parts by weight of solid dispersion carrier in a water bath at 70-80 DEG C, and then adding the used 2-16 parts by weight of absolute ethyl alcohol to dissolve 1.2-3.6 parts by weight of rifaximin to obtain rifaximin solution, uniformly stirring, steaming away the absolute ethyl alcohol in the water bath at 70-80 DEG C, and then rapidly cooling and solidifying. The suppository disclosed by the invention can ensure the uniform dispersion of main medicine and overcome the problems of low heat resistance and long melting time limit of glycerin gelatine matrix.
Description
Technical field
The invention belongs to field of veterinary, relate to domestic animal rifaximin vaginal suppository and preparation method thereof.
Background technology
Rifaximin (Rifaximin) is the semi-synthetic derivant of Rifamycin Sodium, is intestinal or the topical antibiotics of wide spectrum, efficient, low toxicity.This medicine is developed by Italian Alpha Co., Ltd, at first went on the market in Italy as anti-infection property diarrhoea medicine in 1987, be widely used in Europe, the U.S. etc. afterwards, used at China's clinical medicine through SFDA approval in 2004, and be mainly used in preventing and treating the caused acute and chronic intestinal infection of sensitive organism etc.Report that the listing dosage form has dry suspension, oral capsule, tablet, granule etc.
The rifaximin has a broad antifungal spectrum, antibacterial activity is strong.To the golden Portugal bacterium in the gram positive aerobic bacteria, staphylococcus epidermidis, enterococcus, clostridium difficile etc., to Gram negative escherichia coli, Salmonella, shigella, yersinia and Grain-positive anaerobe all have the height antibacterial activity, the activity of its anti-gram positive bacteria is better than gram-negative bacteria.
Rifaximin is the same with other rifamycinoid antibiotics, and bactericidal action mechanism also is the synthetic of the anti-bacteria RNA by irreversibly being combined with the B-subunit of DNA of bacteria-dependenc RNA polymerase, and finally anti-bacteria protein is synthetic.Since with the combination of enzyme be irreversible, so rifaximin is bactericidal activity to sensitive organism, bring into play rapidly antibacterial action in the part by killing intestinal or local pathogen.
Rifaximin is oral, substantially without absorbing, only has the rifaximin of less than 0.025% to discharge from urine with original shape, so orally be fit to very much prevent and treat enterobacterial infection.Behind the rat single oral rifaximin 100mg/kg, only there is a small amount of medicine (0.2 μ g/ml, 9.6 μ g/ml) in serum and the liver,, reach higher concentration at gastrointestinal mucosa, it is few to distribute at liver, kidney, lung, and most of medicine passes through defecate.Rat single oral rifaximin 25mg/kg 72 hours, the response rate in the feces is 53.4%, the response rate in the urine only is 0.29%.People healthy volunteer fasting is after 9 hours, and oral rifaximin 400mg does not detect this medicine in the plasma sample; In the administration 48 hours, the original shape medicine of visible minute quantity in the urine (be lower than dosage 0.01%).Lactation period or the dry milk phase milch cow, each nipple injects 100mg rifaximin, does not detect rifaximin in the blood plasma.
Compare with traditional rifamycin analog derivative such as rifampicin, rifaximin has strengthened anti-gram negative bacteria effect, does not absorb, and without systemic side effects, does not especially propagate Mycobacterium tuberculosis drug-resistant, it is used at veterinary clinic obtain possibility.Compare with aminoglycoside antibiotics, the rifaximin antimicrobial spectrum is wider, and activity is stronger, and without systemic side effects (do not damage auditory function, can not cause renal insufficiency), intestinal does not need intestinal spasmolytic and intestinal adsorbent drug yet when using.Compare with third generation Development of Fluoroquinolone Antibacterials, rifaximin has increased the effect to positive bacterias such as streptococcus, and safety is larger.
The rifaximin better tolerance, untoward reaction is slight, and toxicity is little.Oral LD50＞the 5g/kg of mice.The SD rat gavages rifaximin 25,50 and 100mg/kg every day, continuous 180d, and except the female rats serum total cholesterol occurs dosage correlation increases, other hematologys, serum biochemistry and histopathologic examination are showed no abnormal change.Rat and rabbit experiment are not all observed fetal toxicity and the teratogenesis toxic action of rifaximin.
At present, rifaximin is mainly used in preventing and treating responsive microbial acute and chronic intestinal infection, diarrhoea syndrome, summer diarrhea, traveler's diarrhea, enterocolitis and the prophylactic of average of operation periods intestinal etc. on the clinical medicine.Related experiment shows that its curative effect is better than the medicines such as ciprofloxacin, neomycin, sulfamethoxazole/Sulfamonomethoxine.With research deeply, its indication expands skin and mucosa local application to, is used for the sensitive organisms such as control periodontal, skin and vagina and infects.
The rifaximin effect is strong, and toxicity is low.European Union, the U.S. have allowed rifaximin to be applied to veterinary clinic, and control is by the microbial part of sensitivity and skin infection.Be mainly used in clinically breast perfusion control mammitis of cow, intrauterine drug administration preventing and controlling cow endometritis, the local infection of external control many animals such as cattle, sheep, goat, horse, rabbit, house pet etc. etc.On China's veterinary clinic, there is not yet its application report.
Suppository is the common formulations of control endometritis, has reported in the dosage form at rifaximin, there is not yet suppository formulation.In the suppository preparation, need to consider the problem of dissolving of insoluble drug.Rifaximin is insoluble in water, and when conventional method prepared suppository, disintegration and stripping were often overtime, affected its antibacterial action.The present invention has announced a kind of ingenious solid dispersions technique that utilizes and has prepared the method that domestic animal is used the rifaximin vaginal suppository, namely adopt solid dispersions technique, rifaximin can be existed with molecularity in solid carrier, and this carrier can be used as again the suppository base material simultaneously, increases suppository hardness.In actual the enforcement, at first with carrier material rifaximin is prepared into solid dispersion, again with the suppository base mix homogeneously, bolt processed can solve preferably the principal agent distribution uniformity and melt the change horizon problem, is conducive to suppository and better plays a role.
Borneolum Syntheticum, thymol, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods have certain antibiotic, antiinflammatory action, are commonly used for the ancillary drug of endometritis suppository, and the antibacterial and anti-inflammation functions that increases principal agent is worked in coordination with in performance, are conducive to the comprehensive therapeutic effect of preparation.
Summary of the invention
The objective of the invention is the above-mentioned deficiency for prior art, a kind of domestic animal rifaximin vaginal suppository is provided.
Another object of the present invention provides the preparation method of this suppository.
Purpose of the present invention can be achieved through the following technical solutions:
Domestic animal rifaximin vaginal suppository comprises following component: rifaximin solid dispersion 8.5-25.5 weight portion, substrate 30-88 weight portion, water: 6.0-12.5 weight portion, surfactant: 0.01-1.0 weight portion; Synergist: 0.01-10.0 weight portion, antiseptic: 0.01-5.0 weight portion, wherein said rifaximin solid dispersion be with solid dispersion carrier 7.3-21.9 weight portion after 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin solution that has obtained with 2-16 weight portion anhydrous alcohol solution 1.2-3.6 weight portion rifaximin, stir evenly, after 70 ℃ of-80 ℃ of water-baths boil off dehydrated alcohol, cooling down is solidified rapidly, and get final product; Described domestic animal with the preparation method of rifaximin vaginal suppository is: at first take hot fusion method to prepare the rifaximin solid dispersion, rifaximin solid dispersion and substrate and surfactant, synergist, the antiseptic of preparation prepared rifaximin suppository by hot fusion method.
Described rifaximin solid dispersion carrier be selected from PEG300, PEG400, PEG600, PEG1000, PEG4000, PEG6000, PEG10000, PVP40000, poloxamer series, Myrij class, brejs, citric acid, succinic acid, carbamide, malic acid, polyvidone, sucrose, stearic acid, glucosan, ethanol, dimethyl formamide, dimethyl acetylamide, propylene glycol, the alpha-pyrrolidone any one or multiple.Preferred rifaximin solid dispersion principal agent and carrier are: contain rifaximin: 1.8-3.6 weight portion, cetomacrogol 1000: 4.0-9.5 weight portion, and Macrogol 4000: 4.5-12.4 weight portion.Dehydrated alcohol: 4.0-16.0 weight portion.
Described suppository base be selected from glycerol, gelatin, PEG300, PEG400, PEG600, PEG1000, PEG4000, PEG6000, PEG10000,, in the poloxamer series, semi-synthetic fatty acid glyceride, cocoa butter, oleum sapii any one or multiple; Preferably glycerine: 55-75 weight portion, gelatin: 10-25 weight portion, cetomacrogol 1000: 4.0-11.5 weight portion and Macrogol 4000: 4.5-14.0 weight portion.
Described surfactant be selected from poloxamer class, sodium lauryl sulphate, tween 80, Tween-60, Tween-40, tween 20, stearyl alcohol sodium sulfonate, polyoxyethylene high fatty alcohol, sucrose ester, sorbitol fatty ester or the soybean phospholipid any one or multiple.
Described synergist be selected from eucalyptus oil, thymol, Borneolum Syntheticum, PEG400, disodium edetate, trisodium citrate, boric acid, sodium bicarbonate or dimethyl sulfoxine any one or multiple.
Described antiseptic be selected from ethylparaben, butyl p-hydroxybenzoate, phenol, domiphen bromide, boric acid, phenylmercuric nitrate, eucalyptus oil, thymol, potassium sorbate, sodium benzoate, thimerosal any one or multiple.
The described domestic animal preparation method of rifaximin vaginal suppository, comprise following steps: 1. with after solid dispersion carrier and 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin ethanol solution, stir evenly, after 70 ℃ of-80 ℃ of water-baths boiled off dehydrated alcohol, cooling down was solidified to get the rifaximin solid dispersion rapidly; 2. take by weighing substrate by formulation content, add entry, heating in water bath, stirring and evenly mixing; 3. the rifaximin solid dispersion is joined in the matrix solution 2., and add synergist, surfactant and antiseptic, behind the stirring and evenly mixing, impouring scribbles in the bolt mould of lubricant to slightly overflowing die orifice; 4. 4 ℃ of-0 ℃ of cold putting a few hours are pruned after solidifying fully and are overflowed part, and die sinking is taken out, and get final product.
Beneficial effect:
The rifaximin antibacterial action is strong, has a broad antifungal spectrum, and multiple Grain-positive, gram negative aerobic bacteria and anaerobe are all had the height antibacterial activity.Rifaximin is oral not to be absorbed, and untoward reaction is slight, and so far there are no, and serious adverse reaction is reported.The antibacterial action characteristics of rifaximin are suitable for preventing and treating the animal endometritis such as domestic animal such as milch cow, cattle, pig, sample, dog very much.
Suppository is the dosage form that more often adopt with medicine in the uterus.Glycerol gelatin matrix is as vaginal suppository substrate, and toughness is stronger, and goods are flexible, frangibility not, but its thermostability (softening temperature) is low, and the substrate thickness is made trouble in addition; On the other hand, because rifaximin is insoluble in water, conventional hot melt prepares rifaximin glycerin gelatine bolt, and medicine is outstanding to be mixed in the substrate, affects its release, even affect its clinical efficacy.
The present invention at first adopts solid dispersions technique, prepares rifaximin solid dispersion solution with appropriate carrier, guarantees the principal agent Uniform Dispersion; And selected carrier possesses and the glycerol gelatin matrix characteristic that mixes, and becomes the part of suppository base, and can overcome the low worry of melting limit for length when becoming of glycerol gelatin matrix thermostability.Optimize suppository base by orthogonal experiment, reach optimal thermal resistance and become the time limit with melting, good looking appearance, thermostability is higher, is difficult for softening.
Specific embodiment:
Embodiment 1:
The preparation of rifaximin solid dispersion
Prescription:
Take by weighing PEG1000, PEG4000 by prescription content, after 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin solution of having used the 8.0g anhydrous alcohol solution, stir evenly, after 70 ℃ of-80 ℃ of water-baths boiled off ethanol, cooling down was solidified rapidly, namely gets the rifaximin solid dispersion.
Embodiment 2
The preparation of rifaximin solid dispersion
Prescription:
Take by weighing PEG1000, poloxamer F68 by prescription content, after 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin solution of having used the 8.0g anhydrous alcohol solution, stir evenly, after 70 ℃ of-80 ℃ of water-baths boiled off ethanol, cooling down was solidified rapidly, namely gets the rifaximin solid dispersion.
Embodiment 3
The preparation of rifaximin solid dispersion
Prescription:
Take by weighing PEG4000, poloxamer F68 by prescription content, after 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin solution of having used the 8.0g anhydrous alcohol solution, stir evenly, after 70 ℃ of-80 ℃ of water-baths boiled off ethanol, cooling down was solidified rapidly, namely gets the rifaximin solid dispersion.
Embodiment 4
Conventional method prepares rifaximin suppository
Prescription:
Method for making: take by weighing gelatin by formulation content, add distilled water dipping 1h, after 40 ℃ of water-bath dissolvings, add glycerol, 65 ℃ of stirred in water bath mixings; Rifaximin is joined in the above-mentioned substrate, and the limit edged stirs, and behind the mixing, impouring scribbles in the bolt mould of lubricant to slightly overflowing die orifice; 4. in 4 ℃ of-0 ℃ of cold putting a few hours, prune after solidifying fully and overflow part, die sinking is taken out, and get final product.
Above-mentioned prescription is the used theory prescription consumption of 50 pieces of suppositorys of preparation.Every piece of heavily about 2 grams of rifaximin vaginal suppository contain principal agent 50mg.44 pieces of actual preparations.
3 test sample thermostabilitys of casual inspection (softening temperature) all are lower than≤and 33.5 ℃.Melt and become the time limit experiment: select 3 of self-control suppositorys, melt according to " Chinese veterinary pharmacopoeia " (2010) and become the inspection of overtime check method.Be limited to when 3 test samples melt just as a result: 70.2min, 78.6min, 81.1min all above 60 minutes, do not meet the pharmacopeia regulation.
Embodiment 5
Substrate influence factor's screening of rifaximin glycerol gelatin matrix vaginal suppository
On embodiment 4 bases, single factors content prepares rifaximin suppository in change glycerol, gelatin, the water-based, finds: when being increased to 30 gram with the components of gelatin consumption by 20 grams, the suppository softening temperature changes little, to become the time limit longer but melt, and the substrate viscosity is too high, also is unfavorable for preparing suppository.The glycerin component consumption reduces, and the suppository softening temperature increases, and to become the time limit longer but melt.
Embodiment 6
The substrate optimization of rifaximin glycerol gelatin matrix vaginal suppository
Select glycerol, solid dispersion carrier material such as cetomacrogol 1000 and Macrogol 4000 three factors, each factor is divided three levels, prepares suppository with hot melt.Be limited to the investigation standard with thermostability with melting when becoming, the substrate ratio that screening is best sees Table 1.
Table 1
As can be known from the above table, melting just in the time limit scope of regulation, qualified prescription number only has 3,5,7 three groups, finally selects the highest substrate prescription of thermostability (softening temperature) to be A
1B
3C
3Its optimum substrate ratio is per 50 pieces of suppositorys (every piece 2 grams), and matrix group becomes: water, 6g; Gelatin, 12g; Glycerol, 60g; PEG1000,5g; PEG4000,5g.
The optimum substrate suppository preparation of embodiment 7 rifaximin vaginal suppositories
Above-mentioned prescription is the used theory prescription consumption of 50 pieces of suppositorys of preparation.Every piece of heavily about 2 grams of rifaximin vaginal suppository contain principal agent 50mg.45 pieces of actual preparations.
Method for making: take by weighing gelatin by formulation content, add distilled water dipping 1h, after 40 ℃ of water-bath dissolvings, add glycerol, 65 ℃ of stirred in water bath mixings; The rifaximin solid dispersion is added wherein, and the limit edged stirs, evenly after, add the stirring and evenly mixings such as Borneolum Syntheticum, sodium lauryl sulphate, 5% ethylparaben alcoholic solution, impouring scribbles in the bolt mould of lubricant to slightly overflowing die orifice; In 4 ℃ of-0 ℃ of cold putting a few hours, to prune after solidifying fully and overflow part, die sinking is taken out, and get final product.
3 test samples of casual inspection melt and become the time limit, and method is respectively with embodiment 4: 54min, 55min, 53min, all dissolvings in 60 minutes meet the pharmacopeia regulation.Softening temperature is: 36.1 ℃, 36.2 ℃, 36.1 ℃
Embodiment 8
Above-mentioned prescription is the used theory prescription consumption of 50 pieces of suppositorys of preparation.Every piece of heavily about 2 grams of rifaximin vaginal suppository contain principal agent 50mg.44 pieces of actual preparations.
Preparation method: with embodiment 7.3 test samples of casual inspection melt and become time limit and softening temperature, and method is respectively with embodiment 4: 59min, 58.5min, 59.3min, all dissolvings in 60 minutes meet the pharmacopeia regulation.Softening temperature is divided into: 36.8 ℃, 36.9 ℃, 36.2 ℃
Embodiment 9
Above-mentioned prescription is the used theory prescription consumption of 50 pieces of suppositorys of preparation.Every piece of heavily about 2 grams of rifaximin vaginal suppository contain principal agent 50mg.45 pieces of actual preparations.
Preparation method: with embodiment 7.3 test samples of casual inspection melt and become time limit and softening temperature, and method is with embodiment 4.Be limited to when 3 test samples melt just as a result: 59.5min, 57.5min, 58.3min, all dissolvings in 60 minutes meet the pharmacopeia regulation.Softening temperature is divided into: 36.0 ℃, 36.1 ℃, 36.2 ℃
Claims (5)
1. utilize the domestic animal rifaximin vaginal suppository of solid dispersions technique preparation, it is characterized in that comprising following component: rifaximin solid dispersion 8.5-25.5 weight portion, substrate 30-88 weight portion, water: 6.0-12.5 weight portions, surfactant: 0.01-1.0 weight portion; Synergist: 0.01-10.0 weight portion, antiseptic: 0.01-5.0 weight portion, wherein said rifaximin solid dispersion be with solid dispersion carrier 7.3-21.9 weight portion after 70 ℃ of-80 ℃ of water-bath meltings, add the rifaximin solution that has obtained with 2-16 weight portion anhydrous alcohol solution 1.2-3.6 weight portion rifaximin, stir evenly, after 70 ℃ of-80 ℃ of water-baths boil off dehydrated alcohol, cooling down is solidified rapidly, and get final product; Described domestic animal with the preparation method of rifaximin vaginal suppository is: at first take hot fusion method to prepare the rifaximin solid dispersion, rifaximin solid dispersion and substrate and surfactant, synergist, the antiseptic of preparation prepared rifaximin suppository by hot fusion method; Described solid dispersion carrier is selected from multiple arbitrarily in any one or PEG300, PEG400 in PEG4000, PEG6000, PEG10000, the poloxamer series, PEG600, PEG1000, PEG4000, PEG6000, PEG10000, the poloxamer series, and described substrate is selected from glycerin gelatine.
2. the domestic animal rifaximin vaginal suppository that utilizes solid dispersions technique preparation according to claim 1, it is characterized in that described surfactant be selected from poloxamer class, sodium lauryl sulphate, tween 80, Tween-60, Tween-40, tween 20, stearyl alcohol sodium sulfonate, polyoxyethylene high fatty alcohol, sucrose ester, sorbitol fatty ester or the soybean phospholipid any one or multiple.
3. the domestic animal rifaximin vaginal suppository that utilizes solid dispersions technique preparation according to claim 1, it is characterized in that described synergist be selected from eucalyptus oil, thymol, Borneolum Syntheticum any one or multiple.
4. the domestic animal rifaximin vaginal suppository that utilizes solid dispersions technique preparation according to claim 1, it is characterized in that described antiseptic be selected from butyl p-hydroxybenzoate, phenol, domiphen bromide, boric acid, phenylmercuric nitrate, eucalyptus oil, thymol, potassium sorbate, sodium benzoate, thimerosal, ethylparaben any one or multiple.
5. domestic animal claimed in claim 1 is characterized in that comprising following steps with the preparation method of rifaximin vaginal suppository:
The solid dispersion carrier after 70 ℃ of-80 ℃ of water-bath meltings, is added the rifaximin ethanol solution, stir evenly, after 70 ℃ of-80 ℃ of water-baths boiled off dehydrated alcohol, cooling down was solidified to get the rifaximin solid dispersion rapidly;
Take by weighing substrate by formulation content, add entry, heating in water bath, stirring and evenly mixing;
The rifaximin solid dispersion is joined
In the solution, and add synergist, surfactant and antiseptic, behind the stirring and evenly mixing, impouring scribbles in the bolt mould of lubricant to slightly overflowing die orifice;
4 ℃ of-0 ℃ of cold putting a few hours are pruned after solidifying fully and are overflowed part, and die sinking is taken out, and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110425645 CN102512358B (en) | 2011-12-16 | 2011-12-16 | Rifaximin vaginal suppository for livestock and preparation method for same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110425645 CN102512358B (en) | 2011-12-16 | 2011-12-16 | Rifaximin vaginal suppository for livestock and preparation method for same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512358A CN102512358A (en) | 2012-06-27 |
| CN102512358B true CN102512358B (en) | 2013-04-10 |
Family
ID=46283621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110425645 Active CN102512358B (en) | 2011-12-16 | 2011-12-16 | Rifaximin vaginal suppository for livestock and preparation method for same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512358B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271902B (en) * | 2013-05-07 | 2015-11-11 | 西安交通大学 | A kind of insoluble medicine solid dispersoid and preparation method thereof |
| AR096469A1 (en) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE TRIAZOLPIRIDINE TYPE COMPOUNDS |
| CN104586855A (en) * | 2014-12-29 | 2015-05-06 | 天津市中升挑战生物科技有限公司 | Compound rifaximin uterus injectant as well as preparation method and application thereof |
| CN105232450B (en) * | 2015-11-17 | 2018-08-17 | 南京多普特兽药研发有限公司 | Breast injection situ-gel containing rifaximin and preparation method thereof |
| CN108498876A (en) * | 2018-05-06 | 2018-09-07 | 李志军 | antibacterial lubricating gel |
| CN113768867A (en) * | 2021-09-16 | 2021-12-10 | 海南海神同洲制药有限公司 | Ofloxacin suppository and preparation method thereof |
| CN113842358B (en) | 2021-10-29 | 2023-05-09 | 佛山市南海东方澳龙制药有限公司 | Uterus injectant for livestock and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1253711B (en) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS |
| CA2643364C (en) * | 2006-03-09 | 2017-06-06 | Salix Pharmaceuticals, Inc. | Rifaximin anti-rectal dysfunction preparation |
| KR101972354B1 (en) * | 2009-10-27 | 2019-04-25 | 루핀 리미티드 | Solid dispersion of rifaximin |
-
2011
- 2011-12-16 CN CN 201110425645 patent/CN102512358B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512358A (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512358B (en) | Rifaximin vaginal suppository for livestock and preparation method for same | |
| CN102415991B (en) | Enrofloxacin long-acting injection and preparation method thereof | |
| CN102440996A (en) | Compound albendazole suspension containing ivermectin nanoemulsion and preparation method thereof | |
| CN102772360B (en) | Doxycycline hydrochloride injection for animals and preparation method for doxycycline hydrochloride injection | |
| CN102716168B (en) | Rifaximin-containing preparation for preventing and treating dairy cow mastitis during dry period and method for preparing rifaximin-containing preparation | |
| CN102488694B (en) | Perfusion medicament for treating milk cow mastitis and preparation method thereof | |
| CN106074543A (en) | A kind of water solublity synergistic composition containing amoxicillin and application thereof | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN101773474A (en) | Preparation method of toltrazuril soluble powder | |
| CN101843624B (en) | Method for preparing soluble powder for treating livestock/poultry coccidiosis | |
| CN104414991A (en) | Tranexamic acid solid sustained-release tablets and preparation method thereof | |
| CN105232450B (en) | Breast injection situ-gel containing rifaximin and preparation method thereof | |
| CN103932974B (en) | Ciclopirox olamine vaginal suppository composition and preparation method thereof | |
| CN102697751A (en) | Enrofloxacin effervescent dispersible tablets special for animals and preparation method of same | |
| CN105456528A (en) | Suppository for treating gynecological inflammation and preparation method thereof | |
| CN105287389A (en) | Amoxicillin soluble powder and preparation method thereof | |
| CN101766564A (en) | High-efficiency water-solubility toltrazuril solution and preparation method thereof | |
| CN101775022A (en) | Ion-pair compound of chelerythrine from Chinese medicine extracts, preparation and application thereof | |
| CN101579306A (en) | Ciclopirox olamine pessary and preparation method thereof | |
| CN101721373B (en) | Solid cefdinir sub-microemulsion and application thereof | |
| CN101584703A (en) | Pharmaceutical composition for treating colpitis and preparation method thereof | |
| CN101623368A (en) | Drug for treating gynecological diseases and preparation technology thereof | |
| CN104622842B (en) | A kind of calcium hydrophenyl sulfonate capsule and preparation method thereof | |
| CN108524467A (en) | A kind of composite sulfamonomethoxine sodium microcapsule formulation and preparation method thereof | |
| CN104622803A (en) | Breast injectant for treating mastitis of lactating dairy cows and preparation method of breast injectant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 210043 Jiangsu Nanjing Qixia District Bagua Zhou street Jiangsu Qixia modern agriculture industrial park Nanjing Agricultural University modern horticulture industry science and Technology Innovation Center Patentee after: NANJING AGRICULTURAL University Address before: 210095 Wei Gang 1, Xuanwu District, Nanjing, Jiangsu Patentee before: Nanjing Agricultural University |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 211225 Jiangsu Nanjing Lishui District Baima Town National Agricultural Science and Technology Park Nanjing Agricultural University base Patentee after: NANJING AGRICULTURAL University Address before: 210043 Jiangsu Nanjing Qixia District Bagua Zhou street Jiangsu Qixia modern agriculture industrial park Nanjing Agricultural University modern horticulture industry science and Technology Innovation Center Patentee before: Nanjing Agricultural University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220907 Address after: Room 2102, Block A, Jincheng International Plaza, Jinshui District, Zhengzhou City, Henan Province, 450003 Patentee after: ZHENGZHOU BARY ANIMAL PHARMACEUTICAL Co.,Ltd. Address before: 211225 Jiangsu Nanjing Lishui District Baima Town National Agricultural Science and Technology Park Nanjing Agricultural University base Patentee before: NANJING AGRICULTURAL University |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 451100 Road north, 200 meters east of the intersection of Huaxia Avenue and Nanhai Avenue, Minggang Office, Zhengzhou Airport Economic Comprehensive Experimental Zone, Zhengzhou City, Henan Province Patentee after: ZHENGZHOU BARY ANIMAL PHARMACEUTICAL Co.,Ltd. Address before: Room 2102, Block A, Jincheng International Plaza, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee before: ZHENGZHOU BARY ANIMAL PHARMACEUTICAL Co.,Ltd. |